#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4.
1-1	0-2	4.	_	_	_	_

#Text=Treatments for Diabetic Foot Ulcers
2-1	3-13	Treatments	abstract[1]	new[1]	coref	9-5[81_1]
2-2	14-17	for	abstract[1]	new[1]	_	_
2-3	18-26	Diabetic	abstract[1]|person[3]	new[1]|new[3]	_	_
2-4	27-31	Foot	abstract[1]|animal|person[3]	new[1]|new|new[3]	_	_
2-5	32-38	Ulcers	abstract[1]|person[3]	new[1]|new[3]	_	_

#Text=One strategy for the management of patients with a DFU is to introduce a multidisciplinary approach and address the multifactorial processes involved in DFUs .
3-1	39-42	One	abstract[4]	new[4]	_	_
3-2	43-51	strategy	abstract[4]	new[4]	_	_
3-3	52-55	for	abstract[4]	new[4]	_	_
3-4	56-59	the	abstract[4]|organization[5]	new[4]|new[5]	coref	12-13[105_5]
3-5	60-70	management	abstract[4]|organization[5]	new[4]|new[5]	_	_
3-6	71-73	of	abstract[4]|organization[5]	new[4]|new[5]	_	_
3-7	74-82	patients	abstract[4]|organization[5]|person[6]	new[4]|new[5]|new[6]	coref	4-64[32_6]
3-8	83-87	with	abstract[4]|organization[5]|person[6]	new[4]|new[5]|new[6]	_	_
3-9	88-89	a	abstract[4]|organization[5]|person[6]|abstract[7]	new[4]|new[5]|new[6]|new[7]	coref	11-13[93_7]
3-10	90-93	DFU	abstract[4]|organization[5]|person[6]|abstract[7]	new[4]|new[5]|new[6]|new[7]	_	_
3-11	94-96	is	_	_	_	_
3-12	97-99	to	_	_	_	_
3-13	100-109	introduce	_	_	_	_
3-14	110-111	a	abstract[8]	new[8]	_	_
3-15	112-129	multidisciplinary	abstract[8]	new[8]	_	_
3-16	130-138	approach	abstract[8]	new[8]	_	_
3-17	139-142	and	_	_	_	_
3-18	143-150	address	_	_	_	_
3-19	151-154	the	abstract[9]	new[9]	_	_
3-20	155-169	multifactorial	abstract[9]	new[9]	_	_
3-21	170-179	processes	abstract[9]	new[9]	_	_
3-22	180-188	involved	abstract[9]	new[9]	_	_
3-23	189-191	in	abstract[9]	new[9]	_	_
3-24	192-196	DFUs	abstract[9]|abstract	new[9]|new	coref	4-43
3-25	197-198	.	_	_	_	_

#Text=The use of multi-disciplinary teams ( MDTs ) that include all relevant specialties ( i.e. , nursing , orthopedics , plastic surgery , vascular surgery , nutrition , and endocrinology departments ) has shown an effect of decreasing the risks associated with DFUs and amputation by 50 – 85 % , lowering costs , and leading to a better quality of life for patients with DFUs .
4-1	199-202	The	abstract[11]	new[11]	_	_
4-2	203-206	use	abstract[11]	new[11]	_	_
4-3	207-209	of	abstract[11]	new[11]	_	_
4-4	210-228	multi-disciplinary	abstract[11]|organization[12]	new[11]|new[12]	_	_
4-5	229-234	teams	abstract[11]|organization[12]	new[11]|new[12]	_	_
4-6	235-236	(	_	_	_	_
4-7	237-241	MDTs	abstract	new	_	_
4-8	242-243	)	_	_	_	_
4-9	244-248	that	_	_	_	_
4-10	249-256	include	_	_	_	_
4-11	257-260	all	abstract[14]	new[14]	appos	4-15[15_14]
4-12	261-269	relevant	abstract[14]	new[14]	_	_
4-13	270-281	specialties	abstract[14]	new[14]	_	_
4-14	282-283	(	_	_	_	_
4-15	284-288	i.e.	abstract[15]|abstract[16]	giv[15]|giv[16]	appos|appos	4-15[16_15]|4-19[0_16]
4-16	289-290	,	abstract[15]|abstract[16]	giv[15]|giv[16]	_	_
4-17	291-298	nursing	abstract[15]|abstract[16]	giv[15]|giv[16]	_	_
4-18	299-300	,	abstract[16]	giv[16]	_	_
4-19	301-312	orthopedics	abstract[16]|abstract	giv[16]|giv	appos	4-21[18_0]
4-20	313-314	,	abstract[16]	giv[16]	_	_
4-21	315-322	plastic	abstract[16]|abstract[18]	giv[16]|giv[18]	appos	4-24[19_18]
4-22	323-330	surgery	abstract[16]|abstract[18]	giv[16]|giv[18]	_	_
4-23	331-332	,	abstract[16]	giv[16]	_	_
4-24	333-341	vascular	abstract[16]|abstract[19]	giv[16]|giv[19]	appos	4-27[0_19]
4-25	342-349	surgery	abstract[16]|abstract[19]	giv[16]|giv[19]	_	_
4-26	350-351	,	abstract[16]	giv[16]	_	_
4-27	352-361	nutrition	abstract[16]|abstract	giv[16]|giv	appos	4-30[22_0]
4-28	362-363	,	abstract[16]	giv[16]	_	_
4-29	364-367	and	abstract[16]	giv[16]	_	_
4-30	368-381	endocrinology	abstract[16]|abstract|abstract[22]	giv[16]|new|giv[22]	_	_
4-31	382-393	departments	abstract[16]|abstract[22]	giv[16]|giv[22]	_	_
4-32	394-395	)	_	_	_	_
4-33	396-399	has	_	_	_	_
4-34	400-405	shown	_	_	_	_
4-35	406-408	an	abstract[23]	new[23]	coref	19-3[152_23]
4-36	409-415	effect	abstract[23]	new[23]	_	_
4-37	416-418	of	abstract[23]	new[23]	_	_
4-38	419-429	decreasing	abstract[23]	new[23]	_	_
4-39	430-433	the	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-40	434-439	risks	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-41	440-450	associated	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-42	451-455	with	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-43	456-460	DFUs	abstract[23]|abstract[24]|abstract|abstract[26]	new[23]|new[24]|giv|giv[26]	coref|coref	4-43[26_0]|4-66[0_26]
4-44	461-464	and	abstract[23]|abstract[24]|abstract[26]	new[23]|new[24]|giv[26]	_	_
4-45	465-475	amputation	abstract[23]|abstract[24]|abstract[26]|event	new[23]|new[24]|giv[26]|new	_	_
4-46	476-478	by	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-47	479-481	50	abstract[23]|abstract[24]|abstract[28]	new[23]|new[24]|new[28]	_	_
4-48	482-483	–	abstract[23]|abstract[24]|abstract[28]	new[23]|new[24]|new[28]	_	_
4-49	484-486	85	abstract[23]|abstract[24]|abstract[28]	new[23]|new[24]|new[28]	_	_
4-50	487-488	%	abstract[23]|abstract[24]|abstract[28]	new[23]|new[24]|new[28]	_	_
4-51	489-490	,	abstract[23]	new[23]	_	_
4-52	491-499	lowering	abstract[23]	new[23]	_	_
4-53	500-505	costs	abstract[23]|abstract	new[23]|new	_	_
4-54	506-507	,	abstract[23]	new[23]	_	_
4-55	508-511	and	abstract[23]	new[23]	_	_
4-56	512-519	leading	abstract[23]	new[23]	_	_
4-57	520-522	to	_	_	_	_
4-58	523-524	a	abstract[30]	new[30]	_	_
4-59	525-531	better	abstract[30]	new[30]	_	_
4-60	532-539	quality	abstract[30]	new[30]	_	_
4-61	540-542	of	abstract[30]	new[30]	_	_
4-62	543-547	life	abstract[30]|abstract	new[30]|new	_	_
4-63	548-551	for	abstract[30]	new[30]	_	_
4-64	552-560	patients	abstract[30]|person[32]	new[30]|giv[32]	coref	11-27[0_32]
4-65	561-565	with	abstract[30]|person[32]	new[30]|giv[32]	_	_
4-66	566-570	DFUs	abstract[30]|person[32]|abstract	new[30]|giv[32]|giv	coref	5-3
4-67	571-572	.	_	_	_	_

#Text=Management of DFUs requires the correct classification of stage and severity .
5-1	573-583	Management	person[34]	new[34]	_	_
5-2	584-586	of	person[34]	new[34]	_	_
5-3	587-591	DFUs	person[34]|abstract	new[34]|giv	coref	6-4
5-4	592-600	requires	_	_	_	_
5-5	601-604	the	abstract[36]	new[36]	_	_
5-6	605-612	correct	abstract[36]	new[36]	_	_
5-7	613-627	classification	abstract[36]	new[36]	_	_
5-8	628-630	of	abstract[36]	new[36]	_	_
5-9	631-636	stage	abstract[36]|abstract	new[36]|new	_	_
5-10	637-640	and	abstract[36]	new[36]	_	_
5-11	641-649	severity	abstract[36]|abstract	new[36]|new	_	_
5-12	650-651	.	_	_	_	_

#Text=Adequate care for DFUs should include a focus on DM control as well as on wound care , proper infection control , relieving pressure , and optimizing blood flow .
6-1	652-660	Adequate	abstract[39]	new[39]	coref	6-16[45_39]
6-2	661-665	care	abstract[39]	new[39]	_	_
6-3	666-669	for	abstract[39]	new[39]	_	_
6-4	670-674	DFUs	abstract[39]|abstract	new[39]|giv	coref	7-10
6-5	675-681	should	_	_	_	_
6-6	682-689	include	_	_	_	_
6-7	690-691	a	abstract[41]	new[41]	_	_
6-8	692-697	focus	abstract[41]	new[41]	_	_
6-9	698-700	on	abstract[41]	new[41]	_	_
6-10	701-703	DM	abstract[41]|person|abstract[43]	new[41]|new|new[43]	coref	6-19[47_43]
6-11	704-711	control	abstract[41]|abstract[43]	new[41]|new[43]	_	_
6-12	712-714	as	_	_	_	_
6-13	715-719	well	_	_	_	_
6-14	720-722	as	_	_	_	_
6-15	723-725	on	_	_	_	_
6-16	726-731	wound	abstract|abstract[45]	new|giv[45]	coref|coref	7-1[50_45]|8-25
6-17	732-736	care	abstract[45]	giv[45]	_	_
6-18	737-738	,	_	_	_	_
6-19	739-745	proper	abstract[47]	giv[47]	coref	7-5[51_47]
6-20	746-755	infection	event|abstract[47]	new|giv[47]	coref	7-25
6-21	756-763	control	abstract[47]	giv[47]	_	_
6-22	764-765	,	_	_	_	_
6-23	766-775	relieving	_	_	_	_
6-24	776-784	pressure	abstract	new	coref	7-20
6-25	785-786	,	_	_	_	_
6-26	787-790	and	_	_	_	_
6-27	791-801	optimizing	_	_	_	_
6-28	802-807	blood	abstract[49]	new[49]	_	_
6-29	808-812	flow	abstract[49]	new[49]	_	_
6-30	813-814	.	_	_	_	_

#Text=The basic care for the control and treatment of DFUs is focused on the management of adequate perfusion , pressure mitigation , control of infection , and debridement .
7-1	815-818	The	abstract[50]	giv[50]	coref	17-34[0_50]
7-2	819-824	basic	abstract[50]	giv[50]	_	_
7-3	825-829	care	abstract[50]	giv[50]	_	_
7-4	830-833	for	abstract[50]	giv[50]	_	_
7-5	834-837	the	abstract[50]|abstract[51]	giv[50]|giv[51]	coref	7-23[58_51]
7-6	838-845	control	abstract[50]|abstract[51]	giv[50]|giv[51]	_	_
7-7	846-849	and	abstract[50]	giv[50]	_	_
7-8	850-859	treatment	abstract[50]|abstract[52]	giv[50]|new[52]	coref	16-1[120_52]
7-9	860-862	of	abstract[50]|abstract[52]	giv[50]|new[52]	_	_
7-10	863-867	DFUs	abstract[50]|abstract[52]|abstract	giv[50]|new[52]|giv	coref	8-10
7-11	868-870	is	_	_	_	_
7-12	871-878	focused	_	_	_	_
7-13	879-881	on	_	_	_	_
7-14	882-885	the	person[54]	new[54]	_	_
7-15	886-896	management	person[54]	new[54]	_	_
7-16	897-899	of	person[54]	new[54]	_	_
7-17	900-908	adequate	person[54]|substance[55]	new[54]|new[55]	_	_
7-18	909-918	perfusion	person[54]|substance[55]	new[54]|new[55]	_	_
7-19	919-920	,	person[54]	new[54]	_	_
7-20	921-929	pressure	person[54]|abstract|abstract[57]	new[54]|giv|new[57]	coref	8-23[68_0]
7-21	930-940	mitigation	person[54]|abstract[57]	new[54]|new[57]	_	_
7-22	941-942	,	person[54]	new[54]	_	_
7-23	943-950	control	person[54]|abstract[58]	new[54]|giv[58]	coref	12-1[100_58]
7-24	951-953	of	person[54]|abstract[58]	new[54]|giv[58]	_	_
7-25	954-963	infection	person[54]|abstract[58]|event	new[54]|giv[58]|giv	_	_
7-26	964-965	,	person[54]	new[54]	_	_
7-27	966-969	and	person[54]	new[54]	_	_
7-28	970-981	debridement	person[54]|event	new[54]|new	_	_
7-29	982-983	.	_	_	_	_

#Text=With technological advancement , other series of therapies for DFUs have been implemented , such as the development of skin substitutes , negative pressure wound therapy , hyperbaric oxygen , the creation of new wound dressings that include growth factors , and the use of tissues from bioengineering .
8-1	984-988	With	_	_	_	_
8-2	989-1002	technological	event[61]	new[61]	_	_
8-3	1003-1014	advancement	event[61]	new[61]	_	_
8-4	1015-1016	,	_	_	_	_
8-5	1017-1022	other	abstract[62]	new[62]	_	_
8-6	1023-1029	series	abstract[62]	new[62]	_	_
8-7	1030-1032	of	abstract[62]	new[62]	_	_
8-8	1033-1042	therapies	abstract[62]|abstract[63]	new[62]|new[63]	coref	26-1[206_63]
8-9	1043-1046	for	abstract[62]|abstract[63]	new[62]|new[63]	_	_
8-10	1047-1051	DFUs	abstract[62]|abstract[63]|abstract	new[62]|new[63]|giv	_	_
8-11	1052-1056	have	_	_	_	_
8-12	1057-1061	been	_	_	_	_
8-13	1062-1073	implemented	_	_	_	_
8-14	1074-1075	,	_	_	_	_
8-15	1076-1080	such	_	_	_	_
8-16	1081-1083	as	_	_	_	_
8-17	1084-1087	the	event[65]	new[65]	_	_
8-18	1088-1099	development	event[65]	new[65]	_	_
8-19	1100-1102	of	event[65]	new[65]	_	_
8-20	1103-1107	skin	event[65]|object|substance[67]	new[65]|new|new[67]	_	_
8-21	1108-1119	substitutes	event[65]|substance[67]	new[65]|new[67]	_	_
8-22	1120-1121	,	event[65]	new[65]	_	_
8-23	1122-1130	negative	event[65]|abstract[68]|abstract[70]	new[65]|giv[68]|new[70]	coref	17-1[132_70]
8-24	1131-1139	pressure	event[65]|abstract[68]|abstract[70]	new[65]|giv[68]|new[70]	_	_
8-25	1140-1145	wound	event[65]|abstract|abstract[70]	new[65]|giv|new[70]	coref	8-35
8-26	1146-1153	therapy	event[65]|abstract[70]	new[65]|new[70]	_	_
8-27	1154-1155	,	event[65]	new[65]	_	_
8-28	1156-1166	hyperbaric	event[65]|substance[71]	new[65]|new[71]	_	_
8-29	1167-1173	oxygen	event[65]|substance[71]	new[65]|new[71]	_	_
8-30	1174-1175	,	_	_	_	_
8-31	1176-1179	the	event[72]	new[72]	_	_
8-32	1180-1188	creation	event[72]	new[72]	_	_
8-33	1189-1191	of	event[72]	new[72]	_	_
8-34	1192-1195	new	event[72]|object[74]	new[72]|new[74]	_	_
8-35	1196-1201	wound	event[72]|abstract|object[74]	new[72]|giv|new[74]	_	_
8-36	1202-1211	dressings	event[72]|object[74]	new[72]|new[74]	_	_
8-37	1212-1216	that	event[72]|object[74]	new[72]|new[74]	_	_
8-38	1217-1224	include	event[72]|object[74]	new[72]|new[74]	_	_
8-39	1225-1231	growth	event[72]|object[74]|abstract|substance[76]	new[72]|new[74]|new|new[76]	coref	26-7[208_76]
8-40	1232-1239	factors	event[72]|object[74]|substance[76]	new[72]|new[74]|new[76]	_	_
8-41	1240-1241	,	_	_	_	_
8-42	1242-1245	and	_	_	_	_
8-43	1246-1249	the	event[77]	new[77]	_	_
8-44	1250-1253	use	event[77]	new[77]	_	_
8-45	1254-1256	of	event[77]	new[77]	_	_
8-46	1257-1264	tissues	event[77]|object[78]	new[77]|new[78]	_	_
8-47	1265-1269	from	event[77]|object[78]	new[77]|new[78]	_	_
8-48	1270-1284	bioengineering	event[77]|object[78]|substance	new[77]|new[78]|new	_	_
8-49	1285-1286	.	_	_	_	_

#Text=In this way , treatments for DPN , PAD , and infections have provided encouraging results .
9-1	1287-1289	In	_	_	_	_
9-2	1290-1294	this	abstract[80]	new[80]	_	_
9-3	1295-1298	way	abstract[80]	new[80]	_	_
9-4	1299-1300	,	_	_	_	_
9-5	1301-1311	treatments	abstract[81]	giv[81]	coref	10-2[86_81]
9-6	1312-1315	for	abstract[81]	giv[81]	_	_
9-7	1316-1319	DPN	abstract[81]|abstract	giv[81]|new	coref	11-1
9-8	1320-1321	,	abstract[81]	giv[81]	_	_
9-9	1322-1325	PAD	abstract[81]|abstract	giv[81]|new	_	_
9-10	1326-1327	,	abstract[81]	giv[81]	_	_
9-11	1328-1331	and	abstract[81]	giv[81]	_	_
9-12	1332-1342	infections	abstract[81]|abstract	giv[81]|new	_	_
9-13	1343-1347	have	_	_	_	_
9-14	1348-1356	provided	_	_	_	_
9-15	1357-1368	encouraging	abstract[85]	new[85]	_	_
9-16	1369-1376	results	abstract[85]	new[85]	_	_
9-17	1377-1378	.	_	_	_	_

#Text=4.1. Treatments for Diabetic Peripheral Neuropathy
10-1	1379-1383	4.1.	_	_	_	_
10-2	1384-1394	Treatments	abstract[86]	giv[86]	coref	16-22[125_86]
10-3	1395-1398	for	abstract[86]	giv[86]	_	_
10-4	1399-1407	Diabetic	abstract[86]|abstract[88]	giv[86]|new[88]	coref	14-7[111_88]
10-5	1408-1418	Peripheral	abstract[86]|abstract|abstract[88]	giv[86]|new|new[88]	_	_
10-6	1419-1429	Neuropathy	abstract[86]|abstract[88]	giv[86]|new[88]	_	_

#Text=DPN is a factor that increases the risk of the appearance of a DFU , owing to the loss of sensation in the limb , making patients vulnerable to trauma .
11-1	1430-1433	DPN	abstract	giv	coref	11-3[90_0]
11-2	1434-1436	is	_	_	_	_
11-3	1437-1438	a	abstract[90]	giv[90]	coref	12-13[0_90]
11-4	1439-1445	factor	abstract[90]	giv[90]	_	_
11-5	1446-1450	that	abstract[90]	giv[90]	_	_
11-6	1451-1460	increases	abstract[90]	giv[90]	_	_
11-7	1461-1464	the	abstract[90]|abstract[91]	giv[90]|new[91]	_	_
11-8	1465-1469	risk	abstract[90]|abstract[91]	giv[90]|new[91]	_	_
11-9	1470-1472	of	abstract[90]|abstract[91]	giv[90]|new[91]	_	_
11-10	1473-1476	the	abstract[90]|abstract[91]|abstract[92]	giv[90]|new[91]|new[92]	_	_
11-11	1477-1487	appearance	abstract[90]|abstract[91]|abstract[92]	giv[90]|new[91]|new[92]	_	_
11-12	1488-1490	of	abstract[90]|abstract[91]|abstract[92]	giv[90]|new[91]|new[92]	_	_
11-13	1491-1492	a	abstract[90]|abstract[91]|abstract[92]|abstract[93]	giv[90]|new[91]|new[92]|giv[93]	coref	30-69[249_93]
11-14	1493-1496	DFU	abstract[90]|abstract[91]|abstract[92]|abstract[93]	giv[90]|new[91]|new[92]|giv[93]	_	_
11-15	1497-1498	,	abstract[90]	giv[90]	_	_
11-16	1499-1504	owing	abstract[90]	giv[90]	_	_
11-17	1505-1507	to	abstract[90]	giv[90]	_	_
11-18	1508-1511	the	abstract[90]|event[94]	giv[90]|new[94]	_	_
11-19	1512-1516	loss	abstract[90]|event[94]	giv[90]|new[94]	_	_
11-20	1517-1519	of	abstract[90]|event[94]	giv[90]|new[94]	_	_
11-21	1520-1529	sensation	abstract[90]|event[94]|abstract[95]	giv[90]|new[94]|new[95]	_	_
11-22	1530-1532	in	abstract[90]|event[94]|abstract[95]	giv[90]|new[94]|new[95]	_	_
11-23	1533-1536	the	abstract[90]|event[94]|abstract[95]|object[96]	giv[90]|new[94]|new[95]|new[96]	_	_
11-24	1537-1541	limb	abstract[90]|event[94]|abstract[95]|object[96]	giv[90]|new[94]|new[95]|new[96]	_	_
11-25	1542-1543	,	_	_	_	_
11-26	1544-1550	making	_	_	_	_
11-27	1551-1559	patients	person	giv	coref	14-12[112_0]
11-28	1560-1570	vulnerable	_	_	_	_
11-29	1571-1573	to	_	_	_	_
11-30	1574-1580	trauma	event	new	_	_
11-31	1581-1582	.	_	_	_	_

#Text=Tight glycemic control is the primary step and a main feature of DPN management .
12-1	1583-1588	Tight	abstract[100]	giv[100]	coref	12-5[101_100]
12-2	1589-1597	glycemic	abstract|abstract[100]	new|giv[100]	_	_
12-3	1598-1605	control	abstract[100]	giv[100]	_	_
12-4	1606-1608	is	_	_	_	_
12-5	1609-1612	the	abstract[101]|abstract[102]	giv[101]|giv[102]	coref	12-5[102_101]
12-6	1613-1620	primary	abstract[101]|abstract[102]	giv[101]|giv[102]	_	_
12-7	1621-1625	step	abstract[101]|abstract[102]	giv[101]|giv[102]	_	_
12-8	1626-1629	and	abstract[102]	giv[102]	_	_
12-9	1630-1631	a	abstract[102]|abstract[103]	giv[102]|new[103]	_	_
12-10	1632-1636	main	abstract[102]|abstract[103]	giv[102]|new[103]	_	_
12-11	1637-1644	feature	abstract[102]|abstract[103]	giv[102]|new[103]	_	_
12-12	1645-1647	of	abstract[102]|abstract[103]	giv[102]|new[103]	_	_
12-13	1648-1651	DPN	abstract[102]|abstract[103]|abstract|organization[105]	giv[102]|new[103]|giv|giv[105]	coref|coref	14-14|18-21[150_105]
12-14	1652-1662	management	abstract[102]|abstract[103]|organization[105]	giv[102]|new[103]|giv[105]	_	_
12-15	1663-1664	.	_	_	_	_

#Text=Normoglycemia is more effectively restored by a pancreas transplant .
13-1	1665-1678	Normoglycemia	substance	new	_	_
13-2	1679-1681	is	_	_	_	_
13-3	1682-1686	more	_	_	_	_
13-4	1687-1698	effectively	_	_	_	_
13-5	1699-1707	restored	_	_	_	_
13-6	1708-1710	by	_	_	_	_
13-7	1711-1712	a	event[108]	new[108]	coref	14-20[116_108]
13-8	1713-1721	pancreas	object|event[108]	new|new[108]	coref	14-21
13-9	1722-1732	transplant	event[108]	new[108]	_	_
13-10	1733-1734	.	_	_	_	_

#Text=Several studies have demonstrated improvement of motor and sensory neuropathy in patients with DPN after they were treated with a pancreas transplant .
14-1	1735-1742	Several	abstract[109]	new[109]	coref	20-8[157_109]
14-2	1743-1750	studies	abstract[109]	new[109]	_	_
14-3	1751-1755	have	_	_	_	_
14-4	1756-1768	demonstrated	_	_	_	_
14-5	1769-1780	improvement	abstract[110]	new[110]	coref	23-37[191_110]
14-6	1781-1783	of	abstract[110]	new[110]	_	_
14-7	1784-1789	motor	abstract[110]|abstract[111]	new[110]|giv[111]	coref	23-29[0_111]
14-8	1790-1793	and	abstract[110]|abstract[111]	new[110]|giv[111]	_	_
14-9	1794-1801	sensory	abstract[110]|abstract[111]	new[110]|giv[111]	_	_
14-10	1802-1812	neuropathy	abstract[110]|abstract[111]	new[110]|giv[111]	_	_
14-11	1813-1815	in	abstract[110]|abstract[111]	new[110]|giv[111]	_	_
14-12	1816-1824	patients	abstract[110]|abstract[111]|person[112]	new[110]|giv[111]|giv[112]	ana	14-16[0_112]
14-13	1825-1829	with	abstract[110]|abstract[111]|person[112]	new[110]|giv[111]|giv[112]	_	_
14-14	1830-1833	DPN	abstract[110]|abstract[111]|person[112]|abstract	new[110]|giv[111]|giv[112]|giv	coref	16-6[121_0]
14-15	1834-1839	after	_	_	_	_
14-16	1840-1844	they	person	giv	coref	30-4[233_0]
14-17	1845-1849	were	_	_	_	_
14-18	1850-1857	treated	_	_	_	_
14-19	1858-1862	with	_	_	_	_
14-20	1863-1864	a	event[116]	giv[116]	_	_
14-21	1865-1873	pancreas	object|event[116]	giv|giv[116]	_	_
14-22	1874-1884	transplant	event[116]	giv[116]	_	_
14-23	1885-1886	.	_	_	_	_

#Text=However , discrepancies exist in the time of response .
15-1	1887-1894	However	_	_	_	_
15-2	1895-1896	,	_	_	_	_
15-3	1897-1910	discrepancies	abstract	new	_	_
15-4	1911-1916	exist	_	_	_	_
15-5	1917-1919	in	_	_	_	_
15-6	1920-1923	the	time[118]	new[118]	_	_
15-7	1924-1928	time	time[118]	new[118]	_	_
15-8	1929-1931	of	time[118]	new[118]	_	_
15-9	1932-1940	response	time[118]|event	new[118]|new	_	_
15-10	1941-1942	.	_	_	_	_

#Text=Pharmacological treatment is used for painful DPN manifested as numbness , burning , stabbing , or excruciating or intractable pain ; only three treatments are approved by the U.S. Food and Drug Administration for the pain associated with DPN , namely , pregabalin , tapentadol , and duloxetine .
16-1	1943-1958	Pharmacological	abstract[120]	giv[120]	coref	24-6[197_120]
16-2	1959-1968	treatment	abstract[120]	giv[120]	_	_
16-3	1969-1971	is	_	_	_	_
16-4	1972-1976	used	_	_	_	_
16-5	1977-1980	for	_	_	_	_
16-6	1981-1988	painful	abstract[121]	giv[121]	coref	16-39[0_121]
16-7	1989-1992	DPN	abstract[121]	giv[121]	_	_
16-8	1993-2003	manifested	abstract[121]	giv[121]	_	_
16-9	2004-2006	as	abstract[121]	giv[121]	_	_
16-10	2007-2015	numbness	abstract[121]|abstract	giv[121]|new	_	_
16-11	2016-2017	,	abstract[121]	giv[121]	_	_
16-12	2018-2025	burning	abstract[121]	giv[121]	_	_
16-13	2026-2027	,	abstract[121]	giv[121]	_	_
16-14	2028-2036	stabbing	abstract[121]|person	giv[121]|new	_	_
16-15	2037-2038	,	abstract[121]	giv[121]	_	_
16-16	2039-2041	or	abstract[121]	giv[121]	_	_
16-17	2042-2054	excruciating	abstract[121]|abstract[124]	giv[121]|new[124]	coref	16-35[127_124]
16-18	2055-2057	or	abstract[121]|abstract[124]	giv[121]|new[124]	_	_
16-19	2058-2069	intractable	abstract[121]|abstract[124]	giv[121]|new[124]	_	_
16-20	2070-2074	pain	abstract[121]|abstract[124]	giv[121]|new[124]	_	_
16-21	2075-2076	;	_	_	_	_
16-22	2077-2081	only	abstract[125]	giv[125]	coref	25-3[198_125]
16-23	2082-2087	three	abstract[125]	giv[125]	_	_
16-24	2088-2098	treatments	abstract[125]	giv[125]	_	_
16-25	2099-2102	are	_	_	_	_
16-26	2103-2111	approved	_	_	_	_
16-27	2112-2114	by	_	_	_	_
16-28	2115-2118	the	organization[126]	new[126]	_	_
16-29	2119-2123	U.S.	organization[126]	new[126]	_	_
16-30	2124-2128	Food	organization[126]	new[126]	_	_
16-31	2129-2132	and	organization[126]	new[126]	_	_
16-32	2133-2137	Drug	organization[126]	new[126]	_	_
16-33	2138-2152	Administration	organization[126]	new[126]	_	_
16-34	2153-2156	for	_	_	_	_
16-35	2157-2160	the	abstract[127]	giv[127]	_	_
16-36	2161-2165	pain	abstract[127]	giv[127]	_	_
16-37	2166-2176	associated	abstract[127]	giv[127]	_	_
16-38	2177-2181	with	abstract[127]	giv[127]	_	_
16-39	2182-2185	DPN	abstract[127]|abstract	giv[127]|giv	coref	21-16
16-40	2186-2187	,	_	_	_	_
16-41	2188-2194	namely	substance[129]	new[129]	_	_
16-42	2195-2196	,	substance[129]	new[129]	_	_
16-43	2197-2207	pregabalin	substance[129]	new[129]	_	_
16-44	2208-2209	,	_	_	_	_
16-45	2210-2220	tapentadol	substance	new	_	_
16-46	2221-2222	,	_	_	_	_
16-47	2223-2226	and	_	_	_	_
16-48	2227-2237	duloxetine	substance	new	_	_
16-49	2238-2239	.	_	_	_	_

#Text=Another pharmacological therapy includes analgesics , such as tramadol , acetaminophen , and some opioids such as oxycodone , which have constipation and nausea as side effects , and must be taken with care because they can be misused .
17-1	2240-2247	Another	abstract[132]	giv[132]	coref	27-9[213_132]
17-2	2248-2263	pharmacological	abstract[132]	giv[132]	_	_
17-3	2264-2271	therapy	abstract[132]	giv[132]	_	_
17-4	2272-2280	includes	_	_	_	_
17-5	2281-2291	analgesics	abstract[133]	new[133]	_	_
17-6	2292-2293	,	abstract[133]	new[133]	_	_
17-7	2294-2298	such	abstract[133]	new[133]	_	_
17-8	2299-2301	as	abstract[133]	new[133]	_	_
17-9	2302-2310	tramadol	abstract[133]|substance	new[133]|new	_	_
17-10	2311-2312	,	abstract[133]	new[133]	_	_
17-11	2313-2326	acetaminophen	abstract[133]|substance	new[133]|new	_	_
17-12	2327-2328	,	abstract[133]	new[133]	_	_
17-13	2329-2332	and	abstract[133]	new[133]	_	_
17-14	2333-2337	some	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-15	2338-2345	opioids	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-16	2346-2350	such	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-17	2351-2353	as	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-18	2354-2363	oxycodone	abstract[133]|abstract[136]|substance	new[133]|new[136]|new	_	_
17-19	2364-2365	,	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-20	2366-2371	which	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-21	2372-2376	have	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-22	2377-2389	constipation	abstract[133]|abstract[136]|abstract	new[133]|new[136]|new	coref	26-25[211_0]
17-23	2390-2393	and	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-24	2394-2400	nausea	abstract[133]|abstract[136]|abstract	new[133]|new[136]|new	_	_
17-25	2401-2403	as	abstract[133]|abstract[136]	new[133]|new[136]	_	_
17-26	2404-2408	side	abstract[133]|abstract[136]|abstract[140]	new[133]|new[136]|new[140]	ana	17-36[0_140]
17-27	2409-2416	effects	abstract[133]|abstract[136]|abstract[140]	new[133]|new[136]|new[140]	_	_
17-28	2417-2418	,	_	_	_	_
17-29	2419-2422	and	_	_	_	_
17-30	2423-2427	must	_	_	_	_
17-31	2428-2430	be	_	_	_	_
17-32	2431-2436	taken	_	_	_	_
17-33	2437-2441	with	_	_	_	_
17-34	2442-2446	care	abstract	giv	_	_
17-35	2447-2454	because	_	_	_	_
17-36	2455-2459	they	abstract	giv	coref	19-17[156_0]
17-37	2460-2463	can	_	_	_	_
17-38	2464-2466	be	_	_	_	_
17-39	2467-2474	misused	_	_	_	_
17-40	2475-2476	.	_	_	_	_

#Text=Therapy with antidepressants such as amitriptyline , nortriptyline , and venlafaxine , among others , has shown an efficacy in neuropathic pain management .
18-1	2477-2484	Therapy	event[143]	new[143]	_	_
18-2	2485-2489	with	event[143]	new[143]	_	_
18-3	2490-2505	antidepressants	event[143]|substance[144]	new[143]|new[144]	_	_
18-4	2506-2510	such	event[143]|substance[144]	new[143]|new[144]	_	_
18-5	2511-2513	as	event[143]|substance[144]	new[143]|new[144]	_	_
18-6	2514-2527	amitriptyline	event[143]|substance[144]|substance	new[143]|new[144]|new	_	_
18-7	2528-2529	,	event[143]|substance[144]	new[143]|new[144]	_	_
18-8	2530-2543	nortriptyline	event[143]|substance[144]|substance	new[143]|new[144]|new	_	_
18-9	2544-2545	,	event[143]|substance[144]	new[143]|new[144]	_	_
18-10	2546-2549	and	event[143]|substance[144]	new[143]|new[144]	_	_
18-11	2550-2561	venlafaxine	event[143]|substance[144]|animal	new[143]|new[144]|new	_	_
18-12	2562-2563	,	event[143]	new[143]	_	_
18-13	2564-2569	among	event[143]	new[143]	_	_
18-14	2570-2576	others	event[143]	new[143]	_	_
18-15	2577-2578	,	_	_	_	_
18-16	2579-2582	has	_	_	_	_
18-17	2583-2588	shown	_	_	_	_
18-18	2589-2591	an	abstract[148]	new[148]	_	_
18-19	2592-2600	efficacy	abstract[148]	new[148]	_	_
18-20	2601-2603	in	abstract[148]	new[148]	_	_
18-21	2604-2615	neuropathic	abstract[148]|person[149]|organization[150]	new[148]|new[149]|giv[150]	ana	19-1[0_150]
18-22	2616-2620	pain	abstract[148]|person[149]|organization[150]	new[148]|new[149]|giv[150]	_	_
18-23	2621-2631	management	abstract[148]|organization[150]	new[148]|giv[150]	_	_
18-24	2632-2633	.	_	_	_	_

#Text=It has an effect on the recapture of noradrenaline and serotonin , as well as on muscarinic effects .
19-1	2634-2636	It	organization	giv	_	_
19-2	2637-2640	has	_	_	_	_
19-3	2641-2643	an	abstract[152]	giv[152]	_	_
19-4	2644-2650	effect	abstract[152]	giv[152]	_	_
19-5	2651-2653	on	abstract[152]	giv[152]	_	_
19-6	2654-2657	the	abstract[152]|event[153]	giv[152]|new[153]	_	_
19-7	2658-2667	recapture	abstract[152]|event[153]	giv[152]|new[153]	_	_
19-8	2668-2670	of	abstract[152]|event[153]	giv[152]|new[153]	_	_
19-9	2671-2684	noradrenaline	abstract[152]|event[153]|substance	giv[152]|new[153]|new	_	_
19-10	2685-2688	and	abstract[152]|event[153]	giv[152]|new[153]	_	_
19-11	2689-2698	serotonin	abstract[152]|event[153]|substance	giv[152]|new[153]|new	_	_
19-12	2699-2700	,	_	_	_	_
19-13	2701-2703	as	_	_	_	_
19-14	2704-2708	well	_	_	_	_
19-15	2709-2711	as	_	_	_	_
19-16	2712-2714	on	_	_	_	_
19-17	2715-2725	muscarinic	abstract[156]	giv[156]	coref	22-11[175_156]
19-18	2726-2733	effects	abstract[156]	giv[156]	_	_
19-19	2734-2735	.	_	_	_	_

#Text=In spite of this , there are limited studies evaluating these drugs because their doses in clinical trials are not entirely reproducible in clinical practice .
20-1	2736-2738	In	_	_	_	_
20-2	2739-2744	spite	_	_	_	_
20-3	2745-2747	of	_	_	_	_
20-4	2748-2752	this	_	_	_	_
20-5	2753-2754	,	_	_	_	_
20-6	2755-2760	there	_	_	_	_
20-7	2761-2764	are	_	_	_	_
20-8	2765-2772	limited	abstract[157]	giv[157]	_	_
20-9	2773-2780	studies	abstract[157]	giv[157]	_	_
20-10	2781-2791	evaluating	abstract[157]	giv[157]	_	_
20-11	2792-2797	these	abstract[157]|substance[158]	giv[157]|new[158]	ana	20-14[0_158]
20-12	2798-2803	drugs	abstract[157]|substance[158]	giv[157]|new[158]	_	_
20-13	2804-2811	because	_	_	_	_
20-14	2812-2817	their	substance|abstract[160]	giv|new[160]	coref	27-12[214_160]
20-15	2818-2823	doses	abstract[160]	new[160]	_	_
20-16	2824-2826	in	abstract[160]	new[160]	_	_
20-17	2827-2835	clinical	abstract[160]|abstract[161]	new[160]|new[161]	coref	22-1[173_161]
20-18	2836-2842	trials	abstract[160]|abstract[161]	new[160]|new[161]	_	_
20-19	2843-2846	are	_	_	_	_
20-20	2847-2850	not	_	_	_	_
20-21	2851-2859	entirely	_	_	_	_
20-22	2860-2872	reproducible	_	_	_	_
20-23	2873-2875	in	_	_	_	_
20-24	2876-2884	clinical	abstract[162]	new[162]	_	_
20-25	2885-2893	practice	abstract[162]	new[162]	_	_
20-26	2894-2895	.	_	_	_	_

#Text=Alpha-lipoic acid ( ALA ) has been suggested as a potential therapeutic agent in treating DPN ; its antioxidant capacity seems to delay or reverse damages to peripheral nerves .
21-1	2896-2908	Alpha-lipoic	abstract|substance[164]	new|new[164]	_	_
21-2	2909-2913	acid	substance[164]	new[164]	_	_
21-3	2914-2915	(	_	_	_	_
21-4	2916-2919	ALA	place	new	coref	22-14
21-5	2920-2921	)	_	_	_	_
21-6	2922-2925	has	_	_	_	_
21-7	2926-2930	been	_	_	_	_
21-8	2931-2940	suggested	_	_	_	_
21-9	2941-2943	as	_	_	_	_
21-10	2944-2945	a	substance[166]	new[166]	ana	21-18[0_166]
21-11	2946-2955	potential	substance[166]	new[166]	_	_
21-12	2956-2967	therapeutic	substance[166]	new[166]	_	_
21-13	2968-2973	agent	substance[166]	new[166]	_	_
21-14	2974-2976	in	substance[166]	new[166]	_	_
21-15	2977-2985	treating	substance[166]	new[166]	_	_
21-16	2986-2989	DPN	substance[166]|abstract	new[166]|giv	coref	25-27
21-17	2990-2991	;	_	_	_	_
21-18	2992-2995	its	substance|abstract[170]	giv|new[170]	_	_
21-19	2996-3007	antioxidant	person|abstract[170]	new|new[170]	_	_
21-20	3008-3016	capacity	abstract[170]	new[170]	_	_
21-21	3017-3022	seems	_	_	_	_
21-22	3023-3025	to	_	_	_	_
21-23	3026-3031	delay	_	_	_	_
21-24	3032-3034	or	_	_	_	_
21-25	3035-3042	reverse	_	_	_	_
21-26	3043-3050	damages	event[171]	new[171]	_	_
21-27	3051-3053	to	event[171]	new[171]	_	_
21-28	3054-3064	peripheral	event[171]|object[172]	new[171]|new[172]	_	_
21-29	3065-3071	nerves	event[171]|object[172]	new[171]|new[172]	_	_
21-30	3072-3073	.	_	_	_	_

#Text=Several human randomized controlled trials ( RCTs ) have investigated the effects of ALA in the development of diabetic nephropathy .
22-1	3074-3081	Several	abstract[173]	giv[173]	appos	22-7[0_173]
22-2	3082-3087	human	abstract[173]	giv[173]	_	_
22-3	3088-3098	randomized	abstract[173]	giv[173]	_	_
22-4	3099-3109	controlled	abstract[173]	giv[173]	_	_
22-5	3110-3116	trials	abstract[173]	giv[173]	_	_
22-6	3117-3118	(	_	_	_	_
22-7	3119-3123	RCTs	abstract	giv	coref	23-4[180_0]
22-8	3124-3125	)	_	_	_	_
22-9	3126-3130	have	_	_	_	_
22-10	3131-3143	investigated	_	_	_	_
22-11	3144-3147	the	abstract[175]	giv[175]	_	_
22-12	3148-3155	effects	abstract[175]	giv[175]	_	_
22-13	3156-3158	of	abstract[175]	giv[175]	_	_
22-14	3159-3162	ALA	abstract[175]|place	giv[175]|giv	coref	23-18[184_0]
22-15	3163-3165	in	abstract[175]	giv[175]	_	_
22-16	3166-3169	the	abstract[175]|event[177]	giv[175]|new[177]	_	_
22-17	3170-3181	development	abstract[175]|event[177]	giv[175]|new[177]	_	_
22-18	3182-3184	of	abstract[175]|event[177]	giv[175]|new[177]	_	_
22-19	3185-3193	diabetic	abstract[175]|event[177]|abstract[178]	giv[175]|new[177]|new[178]	_	_
22-20	3194-3205	nephropathy	abstract[175]|event[177]|abstract[178]	giv[175]|new[177]|new[178]	_	_
22-21	3206-3207	.	_	_	_	_

#Text=A meta-analysis of four RCTs ( n = 653 ) showed that , compared with placebo , intravenous ALA ( 600 mg per day ) decreased symptoms of neuropathy when administered for three weeks , but symptom improvement with oral ALA ( >600 mg per day for 3 – 5 weeks ) was not clinically significant .
23-1	3208-3209	A	abstract[179]	new[179]	_	_
23-2	3210-3223	meta-analysis	abstract[179]	new[179]	_	_
23-3	3224-3226	of	abstract[179]	new[179]	_	_
23-4	3227-3231	four	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
23-5	3232-3236	RCTs	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
23-6	3237-3238	(	_	_	_	_
23-7	3239-3240	n	abstract	new	_	_
23-8	3241-3242	=	_	_	_	_
23-9	3243-3246	653	abstract	new	_	_
23-10	3247-3248	)	_	_	_	_
23-11	3249-3255	showed	_	_	_	_
23-12	3256-3260	that	_	_	_	_
23-13	3261-3262	,	_	_	_	_
23-14	3263-3271	compared	_	_	_	_
23-15	3272-3276	with	_	_	_	_
23-16	3277-3284	placebo	substance	new	_	_
23-17	3285-3286	,	_	_	_	_
23-18	3287-3298	intravenous	place[184]	giv[184]	coref	23-40[192_184]
23-19	3299-3302	ALA	place[184]	giv[184]	_	_
23-20	3303-3304	(	_	_	_	_
23-21	3305-3308	600	substance[185]	new[185]	_	_
23-22	3309-3311	mg	substance[185]	new[185]	_	_
23-23	3312-3315	per	substance[185]	new[185]	_	_
23-24	3316-3319	day	substance[185]|time	new[185]|new	coref	23-46
23-25	3320-3321	)	_	_	_	_
23-26	3322-3331	decreased	_	_	_	_
23-27	3332-3340	symptoms	abstract[187]	new[187]	_	_
23-28	3341-3343	of	abstract[187]	new[187]	_	_
23-29	3344-3354	neuropathy	abstract[187]|abstract	new[187]|giv	_	_
23-30	3355-3359	when	_	_	_	_
23-31	3360-3372	administered	_	_	_	_
23-32	3373-3376	for	_	_	_	_
23-33	3377-3382	three	time[189]	new[189]	coref	23-48[195_189]
23-34	3383-3388	weeks	time[189]	new[189]	_	_
23-35	3389-3390	,	_	_	_	_
23-36	3391-3394	but	_	_	_	_
23-37	3395-3402	symptom	abstract|abstract[191]	new|giv[191]	_	_
23-38	3403-3414	improvement	abstract[191]	giv[191]	_	_
23-39	3415-3419	with	abstract[191]	giv[191]	_	_
23-40	3420-3424	oral	abstract[191]|place[192]	giv[191]|giv[192]	_	_
23-41	3425-3428	ALA	abstract[191]|place[192]	giv[191]|giv[192]	_	_
23-42	3429-3430	(	abstract[191]|place[192]	giv[191]|giv[192]	_	_
23-43	3431-3435	>600	abstract[191]|place[192]|substance[193]	giv[191]|giv[192]|new[193]	_	_
23-44	3436-3438	mg	abstract[191]|place[192]|substance[193]	giv[191]|giv[192]|new[193]	_	_
23-45	3439-3442	per	abstract[191]|place[192]|substance[193]	giv[191]|giv[192]|new[193]	_	_
23-46	3443-3446	day	abstract[191]|place[192]|substance[193]|time	giv[191]|giv[192]|new[193]|giv	_	_
23-47	3447-3450	for	abstract[191]|place[192]	giv[191]|giv[192]	_	_
23-48	3451-3452	3	abstract[191]|place[192]|time[195]	giv[191]|giv[192]|giv[195]	_	_
23-49	3453-3454	–	abstract[191]|place[192]|time[195]	giv[191]|giv[192]|giv[195]	_	_
23-50	3455-3456	5	abstract[191]|place[192]|time[195]	giv[191]|giv[192]|giv[195]	_	_
23-51	3457-3462	weeks	abstract[191]|place[192]|time[195]	giv[191]|giv[192]|giv[195]	_	_
23-52	3463-3464	)	abstract[191]|place[192]	giv[191]|giv[192]	_	_
23-53	3465-3468	was	_	_	_	_
23-54	3469-3472	not	_	_	_	_
23-55	3473-3483	clinically	_	_	_	_
23-56	3484-3495	significant	_	_	_	_
23-57	3496-3497	.	_	_	_	_

#Text=There is no evidence evaluating long-term treatment .
24-1	3498-3503	There	_	_	_	_
24-2	3504-3506	is	_	_	_	_
24-3	3507-3509	no	abstract[196]	new[196]	_	_
24-4	3510-3518	evidence	abstract[196]	new[196]	_	_
24-5	3519-3529	evaluating	abstract[196]	new[196]	_	_
24-6	3530-3539	long-term	abstract[196]|abstract[197]	new[196]|giv[197]	coref	25-23[204_197]
24-7	3540-3549	treatment	abstract[196]|abstract[197]	new[196]|giv[197]	_	_
24-8	3550-3551	.	_	_	_	_

#Text=Currently , treatments based on the use of mesenchymal stem cells ( MSC ) derived from adipose tissue have been considered as a potential treatment against DPN .
25-1	3552-3561	Currently	_	_	_	_
25-2	3562-3563	,	_	_	_	_
25-3	3564-3574	treatments	abstract[198]	giv[198]	coref	29-2[229_198]
25-4	3575-3580	based	abstract[198]	giv[198]	_	_
25-5	3581-3583	on	abstract[198]	giv[198]	_	_
25-6	3584-3587	the	abstract[198]|abstract[199]	giv[198]|new[199]	_	_
25-7	3588-3591	use	abstract[198]|abstract[199]	giv[198]|new[199]	_	_
25-8	3592-3594	of	abstract[198]|abstract[199]	giv[198]|new[199]	_	_
25-9	3595-3606	mesenchymal	abstract[198]|abstract[199]|object[200]	giv[198]|new[199]|new[200]	_	_
25-10	3607-3611	stem	abstract[198]|abstract[199]|object[200]	giv[198]|new[199]|new[200]	_	_
25-11	3612-3617	cells	abstract[198]|abstract[199]|object[200]	giv[198]|new[199]|new[200]	_	_
25-12	3618-3619	(	_	_	_	_
25-13	3620-3623	MSC	abstract	new	_	_
25-14	3624-3625	)	_	_	_	_
25-15	3626-3633	derived	_	_	_	_
25-16	3634-3638	from	_	_	_	_
25-17	3639-3646	adipose	abstract|object[203]	new|new[203]	_	_
25-18	3647-3653	tissue	object[203]	new[203]	_	_
25-19	3654-3658	have	_	_	_	_
25-20	3659-3663	been	_	_	_	_
25-21	3664-3674	considered	_	_	_	_
25-22	3675-3677	as	_	_	_	_
25-23	3678-3679	a	abstract[204]	giv[204]	coref	28-8[222_204]
25-24	3680-3689	potential	abstract[204]	giv[204]	_	_
25-25	3690-3699	treatment	abstract[204]	giv[204]	_	_
25-26	3700-3707	against	abstract[204]	giv[204]	_	_
25-27	3708-3711	DPN	abstract[204]|abstract	giv[204]|giv	coref	28-21
25-28	3712-3713	.	_	_	_	_

#Text=These therapies promote the production of pro-angiogenic , neuroprotective , and anti-inflammatory factors , which have a positive impact on the clinical manifestations of the disease .
26-1	3714-3719	These	abstract[206]	giv[206]	_	_
26-2	3720-3729	therapies	abstract[206]	giv[206]	_	_
26-3	3730-3737	promote	_	_	_	_
26-4	3738-3741	the	abstract[207]	new[207]	_	_
26-5	3742-3752	production	abstract[207]	new[207]	_	_
26-6	3753-3755	of	abstract[207]	new[207]	_	_
26-7	3756-3770	pro-angiogenic	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-8	3771-3772	,	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-9	3773-3788	neuroprotective	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-10	3789-3790	,	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-11	3791-3794	and	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-12	3795-3812	anti-inflammatory	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-13	3813-3820	factors	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-14	3821-3822	,	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-15	3823-3828	which	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-16	3829-3833	have	abstract[207]|substance[208]	new[207]|giv[208]	_	_
26-17	3834-3835	a	abstract[207]|substance[208]|abstract[209]	new[207]|giv[208]|new[209]	_	_
26-18	3836-3844	positive	abstract[207]|substance[208]|abstract[209]	new[207]|giv[208]|new[209]	_	_
26-19	3845-3851	impact	abstract[207]|substance[208]|abstract[209]	new[207]|giv[208]|new[209]	_	_
26-20	3852-3854	on	abstract[207]|substance[208]|abstract[209]	new[207]|giv[208]|new[209]	_	_
26-21	3855-3858	the	abstract[207]|substance[208]|abstract[209]|event[210]	new[207]|giv[208]|new[209]|new[210]	_	_
26-22	3859-3867	clinical	abstract[207]|substance[208]|abstract[209]|event[210]	new[207]|giv[208]|new[209]|new[210]	_	_
26-23	3868-3882	manifestations	abstract[207]|substance[208]|abstract[209]|event[210]	new[207]|giv[208]|new[209]|new[210]	_	_
26-24	3883-3885	of	abstract[207]|substance[208]|abstract[209]|event[210]	new[207]|giv[208]|new[209]|new[210]	_	_
26-25	3886-3889	the	abstract[207]|substance[208]|abstract[209]|event[210]|abstract[211]	new[207]|giv[208]|new[209]|new[210]|giv[211]	coref	29-4[230_211]
26-26	3890-3897	disease	abstract[207]|substance[208]|abstract[209]|event[210]|abstract[211]	new[207]|giv[208]|new[209]|new[210]|giv[211]	_	_
26-27	3898-3899	.	_	_	_	_

#Text=On the other hand , the use of biological therapy with low doses of IL-6 has been demonstrated to promote improvement of blood flow , decrease chronic inflammation , and regenerate peripheral nerve fibers .
27-1	3900-3902	On	_	_	_	_
27-2	3903-3906	the	_	_	_	_
27-3	3907-3912	other	_	_	_	_
27-4	3913-3917	hand	_	_	_	_
27-5	3918-3919	,	_	_	_	_
27-6	3920-3923	the	event[212]	new[212]	_	_
27-7	3924-3927	use	event[212]	new[212]	_	_
27-8	3928-3930	of	event[212]	new[212]	_	_
27-9	3931-3941	biological	event[212]|abstract[213]	new[212]|giv[213]	_	_
27-10	3942-3949	therapy	event[212]|abstract[213]	new[212]|giv[213]	_	_
27-11	3950-3954	with	event[212]	new[212]	_	_
27-12	3955-3958	low	event[212]|abstract[214]	new[212]|giv[214]	_	_
27-13	3959-3964	doses	event[212]|abstract[214]	new[212]|giv[214]	_	_
27-14	3965-3967	of	event[212]|abstract[214]	new[212]|giv[214]	_	_
27-15	3968-3972	IL-6	event[212]|abstract[214]|abstract	new[212]|giv[214]|new	coref	28-3
27-16	3973-3976	has	_	_	_	_
27-17	3977-3981	been	_	_	_	_
27-18	3982-3994	demonstrated	_	_	_	_
27-19	3995-3997	to	_	_	_	_
27-20	3998-4005	promote	_	_	_	_
27-21	4006-4017	improvement	event[216]	new[216]	_	_
27-22	4018-4020	of	event[216]	new[216]	_	_
27-23	4021-4026	blood	event[216]|abstract[217]	new[216]|new[217]	coref	30-11[235_217]
27-24	4027-4031	flow	event[216]|abstract[217]	new[216]|new[217]	_	_
27-25	4032-4033	,	_	_	_	_
27-26	4034-4042	decrease	_	_	_	_
27-27	4043-4050	chronic	abstract[218]	new[218]	_	_
27-28	4051-4063	inflammation	abstract[218]	new[218]	_	_
27-29	4064-4065	,	_	_	_	_
27-30	4066-4069	and	_	_	_	_
27-31	4070-4080	regenerate	_	_	_	_
27-32	4081-4091	peripheral	abstract[219]|object[220]	new[219]|new[220]	coref	28-18[0_219]
27-33	4092-4097	nerve	abstract[219]|object[220]	new[219]|new[220]	_	_
27-34	4098-4104	fibers	object[220]	new[220]	_	_
27-35	4105-4106	.	_	_	_	_

#Text=Accordingly , IL-6 may prove to be an effective treatment for the protection and/or restoration of peripheral nerve function in DPN ; see Table 1 .
28-1	4107-4118	Accordingly	_	_	_	_
28-2	4119-4120	,	_	_	_	_
28-3	4121-4125	IL-6	abstract	giv	_	_
28-4	4126-4129	may	_	_	_	_
28-5	4130-4135	prove	_	_	_	_
28-6	4136-4138	to	_	_	_	_
28-7	4139-4141	be	_	_	_	_
28-8	4142-4144	an	abstract[222]	giv[222]	_	_
28-9	4145-4154	effective	abstract[222]	giv[222]	_	_
28-10	4155-4164	treatment	abstract[222]	giv[222]	_	_
28-11	4165-4168	for	abstract[222]	giv[222]	_	_
28-12	4169-4172	the	abstract[222]|abstract[223]	giv[222]|new[223]	_	_
28-13	4173-4183	protection	abstract[222]|abstract[223]	giv[222]|new[223]	_	_
28-14	4184-4190	and/or	abstract[222]	giv[222]	_	_
28-15	4191-4202	restoration	abstract[222]|event[224]	giv[222]|new[224]	_	_
28-16	4203-4205	of	abstract[222]|event[224]	giv[222]|new[224]	_	_
28-17	4206-4216	peripheral	abstract[222]|event[224]|abstract[226]	giv[222]|new[224]|new[226]	_	_
28-18	4217-4222	nerve	abstract[222]|event[224]|abstract|abstract[226]	giv[222]|new[224]|giv|new[226]	_	_
28-19	4223-4231	function	abstract[222]|event[224]|abstract[226]	giv[222]|new[224]|new[226]	_	_
28-20	4232-4234	in	abstract[222]|event[224]|abstract[226]	giv[222]|new[224]|new[226]	_	_
28-21	4235-4238	DPN	abstract[222]|event[224]|abstract[226]|abstract	giv[222]|new[224]|new[226]|giv	_	_
28-22	4239-4240	;	_	_	_	_
28-23	4241-4244	see	_	_	_	_
28-24	4245-4250	Table	abstract[228]	new[228]	_	_
28-25	4251-4252	1	abstract[228]	new[228]	_	_
28-26	4253-4254	.	_	_	_	_

#Text=4.2. Treatments for Peripheral Arterial Disease ( Ischemia )
29-1	4255-4259	4.2.	_	_	_	_
29-2	4260-4270	Treatments	abstract[229]	giv[229]	_	_
29-3	4271-4274	for	abstract[229]	giv[229]	_	_
29-4	4275-4285	Peripheral	abstract[229]|abstract[230]	giv[229]|giv[230]	appos	29-8[0_230]
29-5	4286-4294	Arterial	abstract[229]|abstract[230]	giv[229]|giv[230]	_	_
29-6	4295-4302	Disease	abstract[229]|abstract[230]	giv[229]|giv[230]	_	_
29-7	4303-4304	(	_	_	_	_
29-8	4305-4313	Ischemia	abstract	giv	coref	30-1[232_0]
29-9	4314-4315	)	_	_	_	_

#Text=Ischemia presenting in diabetic patients due to a reduction in blood flow that occurs in both small vessels ( microvascular , such as capillaries ) and large vessels ( macrovascular , such as arteries and veins ) , or due to a decrease of angiogenesis , can be treated through revascularization of at least one of the foot arteries to try to restore blood flow in patients with a DFU whose toe pressure is <30 mmHg or transcutaneous oxygen pressure ( TcPO2 ) <25 mmHg , as well as in those who have a DFU that does not heal with pressure on the ankle of <50 mmHg or ankle-brachial index ( ABI ) <0.5 .
30-1	4316-4324	Ischemia	abstract[232]	giv[232]	_	_
30-2	4325-4335	presenting	abstract[232]	giv[232]	_	_
30-3	4336-4338	in	abstract[232]	giv[232]	_	_
30-4	4339-4347	diabetic	abstract[232]|person[233]	giv[232]|giv[233]	coref	30-67[248_233]
30-5	4348-4356	patients	abstract[232]|person[233]	giv[232]|giv[233]	_	_
30-6	4357-4360	due	_	_	_	_
30-7	4361-4363	to	_	_	_	_
30-8	4364-4365	a	event[234]	new[234]	_	_
30-9	4366-4375	reduction	event[234]	new[234]	_	_
30-10	4376-4378	in	event[234]	new[234]	_	_
30-11	4379-4384	blood	event[234]|abstract[235]	new[234]|giv[235]	coref	30-64[247_235]
30-12	4385-4389	flow	event[234]|abstract[235]	new[234]|giv[235]	_	_
30-13	4390-4394	that	event[234]	new[234]	_	_
30-14	4395-4401	occurs	event[234]	new[234]	_	_
30-15	4402-4404	in	event[234]	new[234]	_	_
30-16	4405-4409	both	event[234]|object[236]	new[234]|new[236]	_	_
30-17	4410-4415	small	event[234]|object[236]	new[234]|new[236]	_	_
30-18	4416-4423	vessels	event[234]|object[236]	new[234]|new[236]	_	_
30-19	4424-4425	(	_	_	_	_
30-20	4426-4439	microvascular	_	_	_	_
30-21	4440-4441	,	_	_	_	_
30-22	4442-4446	such	_	_	_	_
30-23	4447-4449	as	_	_	_	_
30-24	4450-4461	capillaries	object	new	_	_
30-25	4462-4463	)	_	_	_	_
30-26	4464-4467	and	_	_	_	_
30-27	4468-4473	large	object[238]	new[238]	_	_
30-28	4474-4481	vessels	object[238]	new[238]	_	_
30-29	4482-4483	(	_	_	_	_
30-30	4484-4497	macrovascular	_	_	_	_
30-31	4498-4499	,	_	_	_	_
30-32	4500-4504	such	_	_	_	_
30-33	4505-4507	as	_	_	_	_
30-34	4508-4516	arteries	object	new	coref	30-57[246_0]
30-35	4517-4520	and	_	_	_	_
30-36	4521-4526	veins	object	new	_	_
30-37	4527-4528	)	_	_	_	_
30-38	4529-4530	,	_	_	_	_
30-39	4531-4533	or	_	_	_	_
30-40	4534-4537	due	_	_	_	_
30-41	4538-4540	to	_	_	_	_
30-42	4541-4542	a	event[241]	new[241]	_	_
30-43	4543-4551	decrease	event[241]	new[241]	_	_
30-44	4552-4554	of	event[241]	new[241]	_	_
30-45	4555-4567	angiogenesis	event[241]|abstract	new[241]|new	_	_
30-46	4568-4569	,	_	_	_	_
30-47	4570-4573	can	_	_	_	_
30-48	4574-4576	be	_	_	_	_
30-49	4577-4584	treated	_	_	_	_
30-50	4585-4592	through	_	_	_	_
30-51	4593-4610	revascularization	event[243]	new[243]	_	_
30-52	4611-4613	of	event[243]	new[243]	_	_
30-53	4614-4616	at	event[243]	new[243]	_	_
30-54	4617-4622	least	event[243]|object[244]	new[243]|new[244]	_	_
30-55	4623-4626	one	event[243]|object[244]	new[243]|new[244]	_	_
30-56	4627-4629	of	event[243]|object[244]	new[243]|new[244]	_	_
30-57	4630-4633	the	event[243]|object[244]|object[246]	new[243]|new[244]|giv[246]	_	_
30-58	4634-4638	foot	event[243]|object[244]|object|object[246]	new[243]|new[244]|new|giv[246]	_	_
30-59	4639-4647	arteries	event[243]|object[244]|object[246]	new[243]|new[244]|giv[246]	_	_
30-60	4648-4650	to	_	_	_	_
30-61	4651-4654	try	_	_	_	_
30-62	4655-4657	to	_	_	_	_
30-63	4658-4665	restore	_	_	_	_
30-64	4666-4671	blood	abstract[247]	giv[247]	_	_
30-65	4672-4676	flow	abstract[247]	giv[247]	_	_
30-66	4677-4679	in	_	_	_	_
30-67	4680-4688	patients	person[248]	giv[248]	_	_
30-68	4689-4693	with	person[248]	giv[248]	_	_
30-69	4694-4695	a	person[248]|abstract[249]	giv[248]|giv[249]	coref	30-94[257_249]
30-70	4696-4699	DFU	person[248]|abstract[249]	giv[248]|giv[249]	_	_
30-71	4700-4705	whose	person[248]|abstract[249]|abstract[251]|abstract[252]	giv[248]|giv[249]|new[251]|new[252]	coref	30-78[254_251]
30-72	4706-4709	toe	person[248]|abstract[249]|object|abstract[251]|abstract[252]	giv[248]|giv[249]|new|new[251]|new[252]	_	_
30-73	4710-4718	pressure	person[248]|abstract[249]|abstract[251]|abstract[252]	giv[248]|giv[249]|new[251]|new[252]	_	_
30-74	4719-4721	is	person[248]|abstract[249]|abstract[252]	giv[248]|giv[249]|new[252]	_	_
30-75	4722-4725	<30	person[248]|abstract[249]|abstract[252]	giv[248]|giv[249]|new[252]	_	_
30-76	4726-4730	mmHg	person[248]|abstract[249]|abstract[252]	giv[248]|giv[249]|new[252]	_	_
30-77	4731-4733	or	person[248]|abstract[249]	giv[248]|giv[249]	_	_
30-78	4734-4748	transcutaneous	person[248]|abstract[249]|abstract[254]	giv[248]|giv[249]|giv[254]	appos	30-82[0_254]
30-79	4749-4755	oxygen	person[248]|abstract[249]|substance|abstract[254]	giv[248]|giv[249]|new|giv[254]	_	_
30-80	4756-4764	pressure	person[248]|abstract[249]|abstract[254]	giv[248]|giv[249]|giv[254]	_	_
30-81	4765-4766	(	person[248]|abstract[249]	giv[248]|giv[249]	_	_
30-82	4767-4772	TcPO2	person[248]|abstract[249]|abstract	giv[248]|giv[249]|giv	coref	30-101[258_0]
30-83	4773-4774	)	person[248]|abstract[249]	giv[248]|giv[249]	_	_
30-84	4775-4778	<25	person[248]|abstract[249]|abstract[256]	giv[248]|giv[249]|new[256]	coref	30-106[260_256]
30-85	4779-4783	mmHg	person[248]|abstract[249]|abstract[256]	giv[248]|giv[249]|new[256]	_	_
30-86	4784-4785	,	_	_	_	_
30-87	4786-4788	as	_	_	_	_
30-88	4789-4793	well	_	_	_	_
30-89	4794-4796	as	_	_	_	_
30-90	4797-4799	in	_	_	_	_
30-91	4800-4805	those	_	_	_	_
30-92	4806-4809	who	_	_	_	_
30-93	4810-4814	have	_	_	_	_
30-94	4815-4816	a	abstract[257]	giv[257]	_	_
30-95	4817-4820	DFU	abstract[257]	giv[257]	_	_
30-96	4821-4825	that	abstract[257]	giv[257]	_	_
30-97	4826-4830	does	abstract[257]	giv[257]	_	_
30-98	4831-4834	not	abstract[257]	giv[257]	_	_
30-99	4835-4839	heal	abstract[257]	giv[257]	_	_
30-100	4840-4844	with	abstract[257]	giv[257]	_	_
30-101	4845-4853	pressure	abstract[257]|abstract[258]	giv[257]|giv[258]	_	_
30-102	4854-4856	on	abstract[257]|abstract[258]	giv[257]|giv[258]	_	_
30-103	4857-4860	the	abstract[257]|abstract[258]|object[259]	giv[257]|giv[258]|new[259]	_	_
30-104	4861-4866	ankle	abstract[257]|abstract[258]|object[259]	giv[257]|giv[258]|new[259]	_	_
30-105	4867-4869	of	abstract[257]|abstract[258]	giv[257]|giv[258]	_	_
30-106	4870-4873	<50	abstract[257]|abstract[258]|abstract[260]	giv[257]|giv[258]|giv[260]	_	_
30-107	4874-4878	mmHg	abstract[257]|abstract[258]|abstract[260]	giv[257]|giv[258]|giv[260]	_	_
30-108	4879-4881	or	abstract[257]|abstract[258]	giv[257]|giv[258]	_	_
30-109	4882-4896	ankle-brachial	abstract[257]|abstract[258]|abstract[261]	giv[257]|giv[258]|new[261]	appos	30-112[0_261]
30-110	4897-4902	index	abstract[257]|abstract[258]|abstract[261]	giv[257]|giv[258]|new[261]	_	_
30-111	4903-4904	(	_	_	_	_
30-112	4905-4908	ABI	abstract	giv	_	_
30-113	4909-4910	)	_	_	_	_
30-114	4911-4915	<0.5	_	_	_	_
30-115	4916-4917	.	_	_	_	_
